Predictors of survival in portopulmonary hypertension: a 20-year experience. Issue 4 (13th December 2021)

• Record Type: Journal Article
• Authors: Aggarwal, Manik; Li, Manshi; Bhardwaj, Abhishek; Wallace, William D.; Wang, Xiaofeng; Carey, William D.; Dweik, Raed A.; Heresi, Gustavo A.; Tonelli, Adriano R.
• Is Part Of: European journal of gastroenterology & hepatology. Volume 34:Issue 4(2022)
• Page Start: 449
• Page End: 456
• Publication Date: 2021-12-13
• Subjects: cirrhosis -- Model for End-Stage Liver Disease score -- mortality -- outcome -- portal hypertension -- pulmonary arterial hypertension; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002322
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Background and objectives: Portopulmonary hypertension (PoPH) is a rare complication of portal hypertension associated with poor survival. Scarce data is available on predictors of survival in PoPH with conflicting results. We sought to characterize the outcomes and variables associated with survival in a large cohort of patients with PoPH in an American population of patients. Study design and methods: We identified PoPH patients from the Cleveland Clinic Pulmonary Hypertension Registry between 1998 and 2019. We collected prespecified data, particularly focusing on hepatic and cardiopulmonary assessments and tested their effect on long-term survival. Results: Eighty patients with PoPH with a mean ± SD age of 54 ± 10 years, (54% females) were included in the analysis. The median Model for End-Stage Liver Disease with sodium (MELD-Na) score was 13.0 (10.0–18.0) at PoPH diagnosis. World Health Association functional class III-IV was noted in 57%. Mean pulmonary arterial pressure was 47 ± 10 mmHg and pulmonary vascular resistance 6.0 ± 2.8 Woods units. A total of 63 (78.5%) patients were started on pulmonary arterial hypertension (PAH)-specific treatment during the first 6 months of diagnosis. Survival rates at 1-, 3- and 5-year were 77, 52 and 34%, respectively. Cardiopulmonary hemodynamics as well as PAH-specific treatment did not affect survival. In the multivariable model, MELD-Na, resting heart rate and the presence of hepatic encephalopathy were independent predictors of survival. Conclusion: PoPH patients have poor 5-year survival which is strongly associated to the severity of underlying liver disease and not to the hemodynamic severity of PoPH; therefore efforts should be focused in facilitating liver transplantation for these patients.